Novartis P/E Ratio
Current P/E Ratio
55.29
High Valuation
Very High - High growth expectations or significantly overvalued
Novartis (NOVARTIND) P/E ratio is 55.29 (High), EPS (TTM) ₹37.74, current price ₹2046.80 on NSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see NOVARTIND screener.
Current Valuation Metrics
P/E Ratio
55.29
Current Price
₹2046.80
EPS (TTM)
₹37.74
Exchange
NSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.75
Sector Median
31.66
Sector Rank
#11 of 199
Sector Percentile
5.5%
NOVARTIND P/E Ratio — Valuation Signal & Historical Context
Novartis P/E 55.29 — signal: Overvalued.
- Stock appears overvalued with PE of 55.29, suggesting caution for new investments
NOVARTIND vs Healthcare Peers — P/E Ratio Comparison
Novartis P/E 55.29 vs Healthcare average 56.75, median 31.66 — range 1.99–747.21.
Sector Average
56.75
Sector Median
31.66
Lowest P/E
1.99
Highest P/E
747.21
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 1.99 | ₹66 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Colinz Laboratories | COLINZ | 3.27 | ₹9 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.03 | ₹6,361 | Low |
| Dipna Pharmachem | DPL | 4.65 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.95 | ₹67 | Low |
| Shelter Pharma | SHELTER | 5.71 | ₹56 | Low |
| GKB Ophthalmics | GKB | 5.9 | ₹33 | Low |
| Kabra Drugs | KABRADG | 6.29 | ₹49 | Low |